About Ensysce
Ensysce is a company based in Houston (United States) founded in 2008. Ensysce has raised $2.5 million across 9 funding rounds from investors including HHS, SBIR and Texas Emerging Technology Fund. The company has 9 employees as of December 31, 2024. Ensysce has completed 1 acquisition, including Signature Therapeutics. Ensysce offers products and services including TAAP™ and MPAR®. Ensysce operates in a competitive market with competitors including PharmaJet, Arecor, Suono Bio, Renovis and Splice Bio, among others.
- Headquarter Houston, United States
- Employees 9 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ensysce Biosciences, Inc.
-
Annual Revenue
$5.21 M (USD)133.58as on Dec 31, 2024
-
Net Profit
-$7.99 M (USD)24.74as on Dec 31, 2024
-
EBITDA
-$6.73 M (USD)37.21as on Dec 31, 2024
-
Total Equity Funding
$2.5 M (USD)
in 9 rounds
-
Latest Funding Round
$4 M (USD), Post-IPO
Nov 17, 2025
-
Investors
HHS
& 2 more
-
Employee Count
9
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ensysce
Ensysce is a publicly listed company on the NASDAQ with ticker symbol ENSC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ensysce
Ensysce offers a comprehensive portfolio of products and services, including TAAP™ and MPAR®.
Reduces drug abuse risks through novel platform for oral prescriptions
Prevents opioid overdose with multi-pill resistant features
People of Ensysce
Unlock access to complete
Unlock access to complete
Funding Insights of Ensysce
Ensysce has successfully raised a total of $2.5M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ensysce
Ensysce has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, SBIR and Texas Emerging Technology Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Federal innovation and scientific achievement services are provided.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Ensysce
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ensysce
Ensysce has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Signature Therapeutics.
Investment portfolio details for Ensysce
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Prodrug formulations are developed to prevent prescription medication misuse.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Ensysce
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Ensysce
Detailed financials for Ensysce
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ensysce Comparisons
Peer comparison for Ensysce
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ensysce
Ensysce operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PharmaJet, Arecor, Suono Bio, Renovis and Splice Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of needle-free injection technology
|
|
| Locked | Locked | Locked |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
|
| Locked | Locked | Locked |
Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract
|
|
| Locked | Locked | Locked |
Drugs for neurological diseases are discovered and developed.
|
|
| Locked | Locked | Locked |
Provider of a proprietary platform for gene therapy
|
Detailed competitors of Ensysce
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ensysce
Complete news archive for Ensysce
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ensysce
Ensysce was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Ensysce is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Lynn Kirkpatrick is the current CEO of Ensysce.
Ensysce is a funded company, having raised a total of $2.5M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Ensysce is 9.
Annual revenue of Ensysce is $5.21M as on Dec 31, 2024.
Ensysce was founded in 2008 and is based in Houston, United States. Operations focus on the biotechnology sector, where single-walled carbon nanotubes are developed for cancer treatment applications. These nanotubes enable delivery of active agents, including small interfering RNA, cancer drugs, and alpha-emitting radiation, into tumor cells while bypassing natural barriers and minimizing exposure to healthy tissues.
Ensysce's top competitors include Oxular, PharmaJet and Splice Bio.
Ensysce offers TAAP™ and MPAR®.
Yes, Ensysce is publicly traded on NASDAQ under the ticker symbol ENSC.
Ensysce has made 1 acquisition, including Signature Therapeutics.
The ticker symbol of Ensysce is ENSC on NASDAQ.